Chemotherapy in head and neck cancer with bleomycin, cisplatinum, and methotrexate.
Results of chemotherapy in head and neck cancers are reported with a regimen of cisplatinum, bleomycin and methotrexate. In 63 previously untreated patients, the overall response rate was 73%, including 13/63 CR and 33/63 PR. The response rate in 20 previously treated tumors was 20%. The chemotherapy protocol was well tolerated without severe complications. Initial chemotherapy as a third modality in addition to radiotherapy and/or surgery is discussed.
Deitmer
T
T
Hals-Nasen-Ohrenklinik, Universität Münster, Federal Republic of Germany.
Urbanitz
D
D
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage
D001761:Bleomycin; D002945:Cisplatin; D008727:Methotrexate